Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Neo-adjuvant Pembrolizumab in vulvar squamous cell carcinoma: a clinical proof-of-concept study Ended

2024-512862-32-00 Vulvar squamous cell carcinoma 4 2023-05-11
A study to see how well CVGBM vaccine works at different doses and how safe it is in patients who had surgery for glioblastoma or astrocytom… Ended

2022-501423-25-00 Surgically Resected Glioblastoma (GBM) or Astrocytoma w 7 2023-05-05
Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer (CheckVAC) Ended

2024-515966-14-00 advanced pancreatic cancer 1 2023-05-03
A clinical trial to investigate EO4010, a novel cancer vaccine therapy, with an immune checkpoint blocker, in patients with previously treat… Ended

2023-509509-62-00 Patients with unresectable, previously treated locally 7 2023-05-03
A Phase I study to evaluate the safety and dosimetry of 68Ga-labelled OncoFAP derivatives in patients with solid tumors Ended

2022-500902-16-00 Patients with breast cancer, colorectal cancer, oesopha 1 2023-04-27
KANDOVA An open multicenter study to evaluate the safety and tolerability of KAND567, in combination with carboplatin therapy, and to determ… Ended

2024-515572-13-00 Recurrent epithelial ovarian, fallopian tube, or primar 9 2023-04-26
Evaluation of Amivantamab Infusion Related Reaction Mitigation Ended

2023-506578-11-00 EGFR-mutated Advanced or Metastatic Non-small Cell Lung 4 2023-04-25
A Phase I Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTA0-Tyr3-Octreotate in Children … Ended

2024-515552-21-00 Recurrent or refractory neuroblastoma. 3 2023-04-17
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended

2022-501259-10-00 Relapsed/Refractory Waldenstrom Macroglobulinemia (WM) 4 2023-04-14
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended

2022-501260-18-00 Relapsed/refractory Richter Transformation (RT) 4 2023-04-14
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancie… Ended

2022-501261-46-00 Relapsed/Refractory Burkitt Lymphoma (BL) 4 2023-04-14
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended

2022-501262-21-00 Relapsed/Refractory Hairy Cell Leukemia 4 2023-04-14
A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants with Advanced/Metastatic Non-Sq… Ended

2022-500608-23-00 Previously Untreated MET Amplified Locally Advanced/Met 4 2023-04-06
Phase I dose escalation study of DPPG2-TSL-DOX combined with hyperthermia in soft tissue sarcoma Ended

2023-507836-19-00 Locally advanced (unresectable) or metastatic soft tiss 1 2023-04-03
A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination w… Ended

2022-501451-87-00 Previously Untreated Advanced NSCLC Harboring KRAS G12C 9 2023-03-31
INCA 32459-101: A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies Ended

2022-501505-13-00 Metastatic melanoma 1 2023-03-31
A phase I of TG6050 in the treatment of patients with metastatic lung cancer Ended

2024-513093-22-00 Non-small cell lung cancer (NSCLC) 1 2023-03-27
A Phase 1b Trial of ARV-471 in Combination with Everolimus in Patients with ER+, HER2– Advanced or Metastatic Breast Cancer Ended

2024-513284-30-00 ER+, HER2– Advanced or Metastatic Breast Cancer 3 2023-03-22
A Phase 1, Open-label, Multicenter Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MK-4464 as Monotherapy and in Combination … Ended

2023-504855-28-00 advanced/metastatic solid tumors 1 2023-03-21
A Phase 1 Study of the SHP2 Inhibitor BBP-398 (formerly known as IACS-15509) in combination with the KRAS-G12C Inhibitor Sotorasib in Patien… Ended

2022-501363-40-00 Advanced or metastatic solid tumors with a KRAS-G12C mu 3 2023-03-17
OMX-0407 Phase I Study Ended

2024-514554-75-00 Previously treated unresectable solid tumours 1 2023-03-16
A single arm trial evaluating the efficacy and safety of EVX-01 in combination with pembrolizumab in adults with unresectable or metastatic … Ended

2024-512393-10-00 unresectable or metastatic melanoma 4 2023-03-15
Debio 0123 in combination with carboplatin and etoposide in adult participants with small cell lung cancer that recurred or progressed after… Ended

2024-510980-40-00 Small cell lung cancer 3 2023-03-09
A Phase 1 Multicenter, Open Label, First-in-Human Dose Escalation Study of AFM28, a Bispecific ICE® that Targets CD123 and CD16A, in patient… Ended

2023-510021-16-00 Refractory/relapsed (R/R) CD123-positive acute myeloid 1 2023-03-08